Monday, February 8, 2021 | 10:00 AM 1:00 PM(US ET)

Instructors:

Richard Altman, Field Application Scientist, Life Science Solutions, Thermo Fisher Scientific

Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research (FNLCR)

Workshop Description:
Protein expression laboratories provide crucial support to drug discovery efforts. The mammalian host cell lines, CHO & HEK293 are indispensable tools for these facilities. This workshop will focus on the background, advantages, challenges, and implementation strategies necessary to fully utilize these well-established cell lines. This workshop combines instruction and case studies in an interactive environment.

Topics to be Covered:

• Brief Historical Overview of CHO and HEK293
• Advantages of Each Cell line
• How to Build Your Mammalian Expression Toolbox
• In a World of Complex Proteins, Which Cell Line Do I Choose?
• Optimization of Expression in Each Cell Line

Who Should Attend:

Protein Expression Scientists of all experience levels
Protein Core/Technologies Lab Managers/Members

Speaker Biographies:

Richard Altman, Field Application Scientist, Life Science Solutions, Thermo Fisher Scientific

Rich Altman has 30 years of experience in protein expression and production. In early 2019, he joined Thermo Fisher Scientific as a Field Application Scientist. Previously, he worked for several pharmaceutical companies, including Amgen, Alexion, Bayer, and Upjohn, on the cloning, expression, purification and characterization of recombinant proteins. This work supported both small-molecule high-throughput screening and protein therapeutic efforts. He received his MS degree from the University of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry.

Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research (FNLCR)

Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) at the Frederick National Laboratory for Cancer Research. The PEL focuses on production of high-quality Ras pathway-related proteins for the National Cancer Institute’s RAS Initiative. These proteins are being used for a wide-ranging attack on Ras biology including structural biology, biophysics, and development of screens and assays for drug discovery. Dr. Esposito received his B.A. in Chemistry at La Salle University in Philadelphia, and his Ph.D. in Biochemistry at the Johns Hopkins University Bloomberg School. Dr. Esposito previously worked for Life Technologies, where he helped to develop the Gateway recombinational cloning system.